Drug-Induced Gambling Disorder : Epidemiology, Neurobiology, and Management
(2023) In Pharmaceutical Medicine 37(1). p.37-52- Abstract
Problematic gambling has been suggested to be a possible consequence of dopaminergic medications used mainly in neurological conditions, i.e. pramipexole and ropinirole, and possibly by one antipsychotic compound, aripiprazole. Patients with Parkinson's disease, restless legs syndrome and other conditions potentially treated with dopamine agonists, as well as patients treated for psychotic disorders, are vulnerable patient groups with theoretically increased risk of developing gambling disorder (GD), for example due to higher rates of mental ill-health in these groups. The aim of the present paper is to review the epidemiological, clinical, and neurobiological evidence of the association between dopaminergic medications and GD, and to... (More)
Problematic gambling has been suggested to be a possible consequence of dopaminergic medications used mainly in neurological conditions, i.e. pramipexole and ropinirole, and possibly by one antipsychotic compound, aripiprazole. Patients with Parkinson's disease, restless legs syndrome and other conditions potentially treated with dopamine agonists, as well as patients treated for psychotic disorders, are vulnerable patient groups with theoretically increased risk of developing gambling disorder (GD), for example due to higher rates of mental ill-health in these groups. The aim of the present paper is to review the epidemiological, clinical, and neurobiological evidence of the association between dopaminergic medications and GD, and to describe risk groups and treatment options. The neurobiology of GD involves the reward and reinforcement system, based mainly on mesocorticolimbic dopamine projections, with the nucleus accumbens being a crucial area for developing addictions to substances and behaviors. The addictive properties of gambling can perhaps be explained by the reward uncertainty that activates dopamine signaling in a pathological manner. Since reward-related learning is mediated by dopamine, it can be altered by dopaminergic medications, possibly leading to increased gambling behavior and a decreased impulse control. A causal relationship between the medications and GD seems likely, but the molecular mechanisms behind this association have not been fully described yet. More research is needed in order to fully outline the clinical picture of GD developing in patient groups with dopaminergic medications, and data are needed on the differentiation of risk in different compounds. In addition, very few interventional studies are available on the management of GD induced by dopaminergic medications. While GD overall can be treated, there is need for treatment studies testing the effectiveness of tapering of the medication or other gambling-specific treatment modalities in these patient groups.
(Less)
- author
- Wolfschlag, Mirjam LU and Håkansson, Anders LU
- organization
- publishing date
- 2023-01-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Gambling/chemically induced, Dopamine/adverse effects, Dopamine Agonists/adverse effects, Parkinson Disease/drug therapy, Restless Legs Syndrome/chemically induced
- in
- Pharmaceutical Medicine
- volume
- 37
- issue
- 1
- pages
- 16 pages
- publisher
- Springer
- external identifiers
-
- scopus:85145854440
- pmid:36611111
- ISSN
- 1178-2595
- DOI
- 10.1007/s40290-022-00453-9
- language
- English
- LU publication?
- yes
- additional info
- © 2023. The Author(s).
- id
- 86207882-5952-43c7-9fc4-e9942bd18ece
- date added to LUP
- 2023-02-02 10:00:10
- date last changed
- 2024-06-13 13:26:55
@article{86207882-5952-43c7-9fc4-e9942bd18ece,
abstract = {{<p>Problematic gambling has been suggested to be a possible consequence of dopaminergic medications used mainly in neurological conditions, i.e. pramipexole and ropinirole, and possibly by one antipsychotic compound, aripiprazole. Patients with Parkinson's disease, restless legs syndrome and other conditions potentially treated with dopamine agonists, as well as patients treated for psychotic disorders, are vulnerable patient groups with theoretically increased risk of developing gambling disorder (GD), for example due to higher rates of mental ill-health in these groups. The aim of the present paper is to review the epidemiological, clinical, and neurobiological evidence of the association between dopaminergic medications and GD, and to describe risk groups and treatment options. The neurobiology of GD involves the reward and reinforcement system, based mainly on mesocorticolimbic dopamine projections, with the nucleus accumbens being a crucial area for developing addictions to substances and behaviors. The addictive properties of gambling can perhaps be explained by the reward uncertainty that activates dopamine signaling in a pathological manner. Since reward-related learning is mediated by dopamine, it can be altered by dopaminergic medications, possibly leading to increased gambling behavior and a decreased impulse control. A causal relationship between the medications and GD seems likely, but the molecular mechanisms behind this association have not been fully described yet. More research is needed in order to fully outline the clinical picture of GD developing in patient groups with dopaminergic medications, and data are needed on the differentiation of risk in different compounds. In addition, very few interventional studies are available on the management of GD induced by dopaminergic medications. While GD overall can be treated, there is need for treatment studies testing the effectiveness of tapering of the medication or other gambling-specific treatment modalities in these patient groups.</p>}},
author = {{Wolfschlag, Mirjam and Håkansson, Anders}},
issn = {{1178-2595}},
keywords = {{Humans; Gambling/chemically induced; Dopamine/adverse effects; Dopamine Agonists/adverse effects; Parkinson Disease/drug therapy; Restless Legs Syndrome/chemically induced}},
language = {{eng}},
month = {{01}},
number = {{1}},
pages = {{37--52}},
publisher = {{Springer}},
series = {{Pharmaceutical Medicine}},
title = {{Drug-Induced Gambling Disorder : Epidemiology, Neurobiology, and Management}},
url = {{http://dx.doi.org/10.1007/s40290-022-00453-9}},
doi = {{10.1007/s40290-022-00453-9}},
volume = {{37}},
year = {{2023}},
}